Selected article for: "negative test and significant difference"

Author: Merzon, Eugene; Green, Ilan; Vinker, Shlomo; Golan‐Cohen, Avivit; Gorohovski, Alessandro; Avramovich, Eva; Frenkel‐Morgenstern, Milana; Magen, Eli
Title: The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID‐19 infection
  • Cord-id: 5utq6bzk
  • Document date: 2021_2_23
  • ID: 5utq6bzk
    Snippet: Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportio
    Document: Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID‐19‐positive group, as compared to the COVID‐19‐negative group (73 (11.03 %) vs. 1548 (15.77%); p=0.001). Aspirin use was associated with lower likelihood of COVID‐19 infection, as compared to non‐users (adjusted OR 0.71 (95% CI, 0.52 to 0.99; p=0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; p<0.001), presented a lower BMI (28.77±5.4 vs. 30.37±4.55; p<0.0189) and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%) and COPD (11, 15.07%) than showed the aspirin non‐users (151, 25.64%, p<0.001; 130, 22.07%, p<0.001; and 43, 7.3%, p=0.023, respectively). Moreover, COVID‐19 disease duration (considered as the time between the first positive and second negative COVID‐19 RT‐PCR test results) among aspirin users was significantly shorter, as compared to aspirin non‐users (19.8±7.8 vs. 21.9± 7.9 p= 0.045). Among hospitalized COVID‐positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (p=0.449). In conclusion, we observed inverse association between the likelihood of COVID‐19 infection, disease duration and mortality and aspirin use for primary prevention.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and adaptive innate: 1
    • ace inhibitor and adaptive innate immunity: 1
    • ace inhibitor and logistic regression: 1, 2, 3, 4, 5, 6, 7
    • ace inhibitor and logistic regression analysis: 1
    • ace inhibitor and lung disease: 1
    • acetylsalicylic acid and acute coronary syndrome: 1, 2
    • acetylsalicylic acid and logistic regression: 1, 2
    • acetylsalicylic acid and logistic regression analysis: 1, 2
    • acetylsalicylic acid and low dose aspirin: 1
    • acute coronary syndrome and adaptive innate: 1
    • acute coronary syndrome and adaptive innate immunity: 1
    • acute coronary syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute coronary syndrome and logistic regression analysis: 1, 2, 3, 4
    • acute coronary syndrome and low dose aspirin: 1
    • adaptive innate and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8
    • adaptive innate and logistic regression analysis: 1, 2, 3
    • adaptive innate and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • adaptive innate immunity and logistic regression: 1, 2, 3
    • adaptive innate immunity and logistic regression analysis: 1